A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Apoptosis
/ drug effects
Carboplatin
/ therapeutic use
Caspase 3
/ metabolism
Cohort Studies
Female
Gossypol
/ analogs & derivatives
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
/ drug therapy
Paclitaxel
/ therapeutic use
Proto-Oncogene Proteins c-bcl-2
/ metabolism
Treatment Outcome
Apoptosis
BCL-2
Chemotherapy
Phase I
Prostate
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
08
03
2019
accepted:
31
05
2019
pubmed:
8
8
2019
medline:
2
6
2021
entrez:
8
8
2019
Statut:
ppublish
Résumé
Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. This phase I trial investigated the MTD of AT-101 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Methods Patients were treated with AT-101 (40 mg) every 12 h on days 1, 2 and 3 of each cycle combined with varying dose levels (DL) of paclitaxel and carboplatin [DL1: paclitaxel (150 mg/m
Identifiants
pubmed: 31388792
doi: 10.1007/s10637-019-00807-2
pii: 10.1007/s10637-019-00807-2
doi:
Substances chimiques
Proto-Oncogene Proteins c-bcl-2
0
Carboplatin
BG3F62OND5
Caspase 3
EC 3.4.22.-
Gossypol
KAV15B369O
Paclitaxel
P88XT4IS4D
gossypol acetic acid
S7RL72610R
Banques de données
ClinicalTrials.gov
['NCT00891072']
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
855-865Subventions
Organisme : NCI NIH HHS
ID : NCI CCSG 72720
Pays : United States
Organisme : NIH HHS
ID : U01CA132194
Pays : United States